N-(2-甲基-4-硝基苯基)苯甲酰胺 | 104478-92-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-甲基-4-硝基苯基)苯甲酰胺
• 英文名称: N-(2-methyl-4-nitrophenyl)benzamide
• CAS: 104478-92-4
• 化学式: C₁₄H₁₂N₂O₃
• 分子量: 256.261
• InChiKey: HTHDLNDPJIVSCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-甲基-4-硝基苯基)苯甲酰胺 在 palladium on activated charcoal 氢气 、 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Rajappa, Srinivasachari; Sreenivasan, Ramaswami; Khalwadekar, Asha, Journal of Chemical Research, Miniprint, 1986, # 5, p. 1657 - 1675

  摘要：

  DOI：
• 作为产物：
  描述：

  N-邻甲苯-苯甲酰胺 在 叔丁基过氧化氢 、 copper(l) iodide 、 叠氮基三甲基硅烷 作用下， 以 癸烷 、 1,2-二氯乙烷 为溶剂， 反应 20.0h， 以10%的产率得到N-(2-甲基-4-硝基苯基)苯甲酰胺
  参考文献：
  名称：

  在有氧条件下，通过TMS叠氮化物和TBHP的同时氧化-氧化，在芳基CH键上进行铜催化的直接硝化

  摘要：

  通过直接的C Ar -H功能化，开发出了前所未有的铜催化原位叠氮化氧化技术，用于苯胺和磺酰胺的硝化。使用TMSN 3和TBHP可以实现这种新颖而高效的硝化方案，而不会排除空气或湿气。已经研究了2-硝基苯胺的合成应用。

  DOI：

  10.1021/acs.orglett.7b01489

文献信息

• Platelet ADP receptor inhibitors
  申请人：Scarborough Robert M.

  公开号：US06906063B2

  公开（公告）日：2005-06-14

  Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  化合物的结构式（I）至（VIII），特别包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，这些衍生物是有效的血小板ADP受体抑制剂。这些衍生物可用于各种药物组合物中，特别适用于预防和/或治疗心血管疾病，尤其是与血栓形成相关的疾病。本发明还涉及一种用于预防或治疗哺乳动物血栓形成的方法，包括给予化合物的结构式（I）至（VIII）或其药学上可接受的盐的治疗有效量。
• Copper‐Catalyzed Mild Nitration of Protected Anilines
  作者：Elier Hernando、Rafael R. Castillo、Nuria Rodríguez、Ramón Gómez Arrayás、Juan C. Carretero

  DOI：10.1002/chem.201404000

  日期：2014.10.20

  A practical copper‐catalyzed direct nitration of protected anilines, by using one equivalent of nitric acid as the nitrating agent, has been developed. This procedure features mild reaction conditions, wide structural scope (with regard to both N‐protecting group and arene substitution), and high functional‐group tolerance. Dinitration with two equivalents of nitric acid is also feasible.

  通过使用一当量的硝酸作为硝化剂，已开发出一种实用的铜催化的被保护的苯胺直接硝化方法。该程序的特点是反应条件温和，结构范围广（就N保护基和芳烃取代​​而言）以及高官能团耐受性。用两当量的硝酸进行消解也是可行的。
• Effective Nitration of Anilides and Acrylamides by<i>tert</i>-Butyl Nitrite
  作者：Yi-fei Ji、Hong Yan、Qi-bai Jiang

  DOI：10.1002/ejoc.201403510

  日期：2015.3

  [10% Cu(NO3)(2)3H(2)O] nitration of anilides was developed by using TBN (tert-butyl nitrite) as a nitrating reagent to give the corresponding nitro-substituted aromatic products in good to excellent yields. The use of TBN also led to the selective nitration of acrylamides at room temperature to afford only the (E) isomer of the nitration product. A series of anilides and acrylamides with a broad array

  硝基化合物是合成有机化学和化学工业中的重要中间体。在此，以TBN（亚硝酸叔丁酯）为硝化试剂，开发了铜催化[10% Cu(NO3)(2)3H(2)O]硝化苯胺的高效硝化反应，得到相应的硝基取代芳烃产物。良好的产量。TBN 的使用还导致丙烯酰胺在室温下选择性硝化以仅提供硝化产物的 (E) 异构体。该程序对一系列具有广泛官能团的苯胺和丙烯酰胺具有良好的耐受性。该合成方法具有原料廉价、反应条件温和、反应速度快、收率高等优点。机理研究表明，一个硝基自由基，
• Quinazoline derivatives and their use as pharmaceuticals
  申请人：AstraZeneca

  公开号：US07709479B1

  公开（公告）日：2010-05-04

  The use of a compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O) or S(O)2, NH or NR12 where R12 is hydrogen or C1-6 alkyl; R5 is selected from a group NHC(O)OR9, NHC(O)R9, NHS(O)2R9, C(O)R9, C(O)OR9, S(O)R9, S(O)OR9, S(O)2OR9, C(O)NR10 R11, S(O)NR10R11 S(O)ONR10R11, where R9, R10 or R11 are various specified organic groups; R6 is hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl; R7 and R8 are various specified organic groups, and R1, R2, R3, R4 are independently selected from halogeno, cyano, nitro, C1-3alkylsulphanyl, —N(OH)R13— (wherein R7 is hydrogen, or C1-3alkyl), or R15X1— (wherein X1 represents a direct bond, —O—, —CH2—, —OCO—, carbonyl, —S—, —SO—, —SO2—, —NR16CO—, —CONR16—, —SO2NR16—, —NR17SO2— or —NR18— (wherein R16, R17 and R18 each independently represents hydrogen, C1-3alkyl or C1-3alkoxy C2-3alkyl), and R9 is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy; in the preparation of a medicament for use in the inhibition of aurora 2 kinase.

  使用化合物式(I)或其盐、酯、酰胺或前药；其中X为O、S、S（O）或S（O）2、NH或NR12，其中R12为氢或C1-6烷基；R5选自NHC（O）OR9、NHC（O）R9、NHS（O）2R9、C（O）R9、C（O）OR9、S（O）R9、S（O）OR9、S（O）2OR9、C（O）NR10R11、S（O）NR10R11、S（O）ONR10R11等一组指定的有机基团，其中R9、R10或R11为不同的指定有机基团；R6为氢、可选取代的烃基或可选取代的杂环烃基；R7和R8为不同的指定有机基团，而R1、R2、R3、R4分别选自卤素、氰基、硝基、C1-3烷基硫醇基、-N（OH）R13-（其中R7为氢或C1-3烷基）或R15X1-（其中X1代表直接键、-O-、-CH2-、-OCO-、羰基、-S-、-SO-、-SO2-、-NR16CO-、-CONR16-、-SO2NR16-、-NR17SO2-或-NR18-（其中R16、R17和R18各自独立地代表氢、C1-3烷基或C1-3烷氧基C2-3烷基），而R9为氢、可选取代的烃基、可选取代的杂环烃基或可选取代的烷氧基，在制备用于抑制极光激酶2的药物时使用。
• &lt;p&gt;Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs&lt;/p&gt;
  作者：Jens Hagenow、Stefanie Hagenow、Kathrin Grau、Mohammad Khanfar、Lena Hefke、Ewgenij Proschak、Holger Stark

  DOI：10.2147/dddt.s236586

  日期：——

  Background: Ligands consisting of two aryl moieties connected via a short spacer were shown to be potent inhibitors of monoamine oxidases (MAO) A and B, which are known as suitable targets in treatment of neurological diseases. Based on this general blueprint, we synthesized a series of 66 small aromatic amide derivatives as novel MAO A/B inhibitors.Methods: The compounds were synthesized, purified and structurally confirmed by spectroscopic methods. Fluorimetric enzymological assays were performed to determine MAO A/B inhibition properties. Mode and reversibility of inhibition was determined for the most potent MAO B inhibitor. Docking poses and pharmacophore models were generated to confirm the in vitro results.Results: N-(2,4-Dinitrophenyl)benzo [d] [1,3]dioxole-5-carboxamide (55, ST-2043) was found to be a reversible competitive moderately selective MAO B inhibitor (IC50 = 56 nM, K-i = 6.3 nM), while N-(2,4-dinitrophenyl)benzamide (7, ST-2023) showed higher preference for MAO A (IC50 = 126 nM). Computational analysis confirmed in vitro binding properties, where the anilides examined possessed high surface complementarity to MAO A/B active sites.Conclusion: The small molecule anilides with different substitution patterns were identified as potent MAO A/B inhibitors, which were active in nanomolar concentrations ranges. These small and easily accessible molecules are promising motifs, especially for newly designed multitargeted ligands taking advantage of these fragments.